Ocumension Therapeutics

Alimera Sciences, Inc. is a pharmaceutical company focused on the research, development, and commercialization of prescription ophthalmic pharmaceuticals, particularly targeting diseases affecting the retina. The company is best known for its product ILUVIEN, an intravitreal implant designed for the treatment of diabetic macular edema (DME), a serious condition that can lead to vision loss in individuals with diabetes. ILUVIEN is administered through a non-surgical procedure, delivering a continuous microdose of fluocinolone acetonide directly to the eye, thereby reducing the need for frequent injections. Alimera Sciences also collaborates with EyePoint Pharmaceuticals for the development of additional corticosteroid delivery technologies aimed at treating various eye conditions. The company markets its products through direct sales and distribution channels, serving physician offices, pharmacies, and hospitals. Founded in 2003, Alimera Sciences is headquartered in Alpharetta, Georgia, and operates internationally, including in markets such as Germany, the United Kingdom, China, and the Middle East.

EyePoint Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing ophthalmic products for the treatment of eye diseases in the United States and Europe. The company offers several FDA-approved products, including ILUVIEN for diabetic macular edema, YUTIQ for chronic non-infectious uveitis, DEXYCU for post-operative ocular inflammation, and Retisert for posterior segment uveitis. Additionally, EyePoint is advancing its pipeline with innovative therapies such as EYP-1901, targeting wet age-related macular degeneration and diabetic retinopathy, and YUTIQ50 for uveitis. The company employs its proprietary Durasert and Verisome technology platforms to create sustained-release drug delivery systems that provide controlled drug delivery over extended periods. EyePoint has established strategic collaborations with various organizations to enhance its product offerings and has a commercial alliance for the joint promotion of DEXYCU. Founded in 1987 and headquartered in Watertown, Massachusetts, EyePoint was formerly known as pSivida Corp. and rebranded in March 2018.